Showing 6,521 - 6,540 results of 29,774 for search '(( a web decrease ) OR ( 50 ((((nn decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 0.86s Refine Results
  1. 6521
  2. 6522
  3. 6523

    Coral reef resilience differs among islands within the Gulf of Mannar, southeast India, following successive coral bleaching events by Raj, K. Diraviya

    Published 2021
    “…Overall, between 2005 and 2017 reefs had a simultaneous decrease in relative coral cover (avg. = ? …”
    Get full text
    Get full text
  4. 6524

    PPM1A is critical for proliferation of intestinal organoids. by Ruyuan Zhou (10197187)

    Published 2021
    “…A dramatic lower number of de novo crypts (D, top panel) and the decreased size of organoids (D, bottom panel) were seen in organoids from PPM1A KO mice, with roughly 50 intestine organoids each group examined. …”
  5. 6525

    Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity by Valentina Noemi Madia (1585285)

    Published 2018
    “…Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives <b>13a</b>, <b>14d</b>, and <b>15</b> that showed IC<sub>50</sub> 0.16–0.82 μM. …”
  6. 6526

    Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity by Valentina Noemi Madia (1585285)

    Published 2018
    “…Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives <b>13a</b>, <b>14d</b>, and <b>15</b> that showed IC<sub>50</sub> 0.16–0.82 μM. …”
  7. 6527

    Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity by Valentina Noemi Madia (1585285)

    Published 2018
    “…Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives <b>13a</b>, <b>14d</b>, and <b>15</b> that showed IC<sub>50</sub> 0.16–0.82 μM. …”
  8. 6528

    Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity by Valentina Noemi Madia (1585285)

    Published 2018
    “…Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives <b>13a</b>, <b>14d</b>, and <b>15</b> that showed IC<sub>50</sub> 0.16–0.82 μM. …”
  9. 6529

    Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity by Valentina Noemi Madia (1585285)

    Published 2018
    “…Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives <b>13a</b>, <b>14d</b>, and <b>15</b> that showed IC<sub>50</sub> 0.16–0.82 μM. …”
  10. 6530

    Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity by Valentina Noemi Madia (1585285)

    Published 2018
    “…Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives <b>13a</b>, <b>14d</b>, and <b>15</b> that showed IC<sub>50</sub> 0.16–0.82 μM. …”
  11. 6531

    Image_1_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.TIF by Hilde L. Orrem (5740313)

    Published 2018
    “…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”
  12. 6532

    Image_2_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.TIF by Hilde L. Orrem (5740313)

    Published 2018
    “…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”
  13. 6533

    Table_1_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.DOCX by Hilde L. Orrem (5740313)

    Published 2018
    “…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”
  14. 6534

    Image_2_Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.jpeg by Peipei Zhou (838409)

    Published 2023
    “…Further subgroup analyses indicated that SGLT2i presented more advantages on longer treatment duration and more serious steatosis in decreasing LSM. For CAP, SGLT2i exhibited a clear advantage in subgroup analyses of longer treatment duration, younger people, dapagliflozin, worse fibrosis, and steatosis.…”
  15. 6535

    Supplementary Material for: Efficacy of Huanglian Jiedu Decoction for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis by Wang M. (3632518)

    Published 2024
    “…This meta-analysis aims to determine the efficacy and safety of HJD in the treatment of T2DM. Methods: A systematic review was conducted across six databases including PubMed, Embase, Cochrane, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang, from their inception to August 24, 2023. …”
  16. 6536

    Table_1_Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.docx by Peipei Zhou (838409)

    Published 2023
    “…Further subgroup analyses indicated that SGLT2i presented more advantages on longer treatment duration and more serious steatosis in decreasing LSM. For CAP, SGLT2i exhibited a clear advantage in subgroup analyses of longer treatment duration, younger people, dapagliflozin, worse fibrosis, and steatosis.…”
  17. 6537

    Image_1_Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.jpeg by Peipei Zhou (838409)

    Published 2023
    “…Further subgroup analyses indicated that SGLT2i presented more advantages on longer treatment duration and more serious steatosis in decreasing LSM. For CAP, SGLT2i exhibited a clear advantage in subgroup analyses of longer treatment duration, younger people, dapagliflozin, worse fibrosis, and steatosis.…”
  18. 6538
  19. 6539
  20. 6540